Fig. 3

TOIDC has a comparable effect on the human-derived cells with the primary hepatocytes. A Representative Nile Red stained images of the vehicle and TOIDC-treated HepG2. Scale bar, 100 µm. B Quantification of (A). C Triglyceride content of HepG2 treated with vehicle or TOIDC. D CCK8 assay of cell viability in TOIDC-treated HepG2. E Representative images of MitoTracker Red staining in HepG2 treated with vehicle or TOIDC (15 µM) for 36 h. Scale bar, 50 µm. F Quantification of (E). Data are presented as mean ± SEM of three independent biological replicates; *P < 0.05; **P < 0.01; ns no significance